Cases & Deals

Celgene files Hatch-Waxman suits against multiple generic pharmaceutical defendants over new dosage strengths of generic versions of Focalin XR®

Clients Celgene Corporation

Jones Day represents Celgene Corporation in separate Hatch-Waxman patent infringement actions against Teva Pharmaceuticals; Actavis South Atlantic; and IntelliPharmaCeutics over proposed new dosage strengths of generic versions of Celgene’s branded drug Focalin XR®.

Celgene Corporation et al. v. Teva Pharmaceuticals USA, Inc., Civil Action No. 2-11-cv-02356 (D.N.J.) (Judge Wigenton); Celgene Corporation et al. v. Actavis South Atlantic LLC, Civil Action No. 2-11-cv-02162 (D.N.J.) (Judge Wigenton); Celgene Corporation et al. v. IntelliPharmaCeutics Corporation, Civil Action No. 2-11-cv-01736 (D.N.J.) (Judge Wigenton)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.